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5* Assessing the impact of unclassiﬁed variants on splicing of CFTR
mRNA: in silico predictions versus ex vivo assays
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To date, many unclassiﬁed variants (UVs), particularly missense or putative splicing
alterations, are described on the CFTR gene. As nasal epithelial cells of patients
are rarely available for CFTR transcripts analysis and as consequences of such
alterations on splicing are not always predictable by speciﬁc softwares, ex vivo
splicing assays are needed to assess the impact of CFTR variants on splicing. We
selected 15 UVs identiﬁed in our laboratory in cystic ﬁbrosis and CFTR-RD (related
disease) patients based on familial, epidemiological and bioinformatics criteria.
Ten variants were intronic, including 8 at noncanonical positions of splice sites,
and 5 were exonic (4 missense and one synonymous variants). Aberrant splicing
was demonstrated for 9 out of the 15 (60%) tested UVs, including 6 intronic
and 3 exonic variants, and resulted more frequently in exon skipping (7/9, 78%).
This study suggests that the three missense variants (M152V, G178R and S902R)
should rather be considered as splicing mutations. Further studies are underway to
establish the functional impact of aberrant splicing due to G178R on mRNA stability
and on CFTR protein expression and activity. Overall, this work revealed 86.7%
(13/15) correlation with bioinformatics predictions with 77.8% speciﬁcity and 100%
sensibility. Finally, our data provide key arguments of pathological signiﬁcance of
the tested variants and illustrate the need to deﬁne functional impact of such UVs
to assist in the interpretation of diagnostic tests and genetic counselling.
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Background: An association between cystic ﬁbrosis transmembrane regulator
(CFTR) gene mutations and infertility, has been hypothesized. This study investi-
gated the frequency of the CFTR gene mutation in a group of consecutive patients
candidate for assisted reproductive techniques, and the relation between CFTR
mutation, IVS8-poliT and Y chromosomal microdeletions.
Methods: 7851 patients (4234 females and 3617 males) were screened for 57 CFTR
gene mutations and IVS8-poliT polymorphism by multiplex PCR; 223/3617 (6.2%)
were azoospermic or oligospermic patients (A/OPs) investigated for Y chromosomal
deletion by multiplex PCR. Frequencies of mutation were separately calculated and
the Chi-square test was used for comparisons.
Results: CFTR mutations were detected in 4.6% of the subjects, a percentage
similar to that reported in the general population. The most common mutation was
DF508/N observed in 1.71% of patients. No difference in the gender distribution
was evidenced.
The IVS8-poly-T showed a frequency of 70.9% for 7T/7T alleles, 19.8% for 7T/9T
alleles, and only 0.20% for 5T/5T alleles. 2/223 A/OPs showed a Y chromosomal
microdeletion and was negative for CFTR mutation; 6/223 azoospermic patients
had CFTR mutation. The following distribution of IVS8-poly-T polymorphism in
A/OPs was detected: 5T/5T = 0.86%, 9T/9T = 0.86%.
Conclusions: Our data show no evidence of associations between azoospermia,
CFTR mutations, IVS8-poly-T and Y-chromosomal microdeletions.
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In our survey, we examine CFTR mutations in 106 patients attending the CF centres
in North of France but residing along the North Sea coast then we assess whether
the clinical phenotypes of two mutations might differ in severity.
Methods: Based on clinical ﬁndings and sweat test, we perform genetic analysis in
106 CF patients among 107. It is realized after PCR ampliﬁcation of genomic DNA
prepared from peripherical blood leukocytes, the F508del mutation is analyzed by
polyacrylamide gel electrophoresis and the CFTR gene coding and ﬂanking regions
by D-HPLC followed by sequencing each abnormal pattern detected to characterize
the variants. We use statistical tests for comparison of clinical phenotypes.
Results: We identify 29 CFTR mutations and variants, 97% of mutations being
characterized. Beside F508del mutation (64.6%), some mutations appear to be
frequent: R553X (5.2%), 394delTT (2.8%), G542X 2789+5G>A (2.3%), N1303K,
3272−26A>G, 1717−1G>A (1.9%), 2184delA, I336K, 3849+10kbC>T, 542del7
(1.4%). 394 delTT, a very rare mutation outside the Nordic countries, is the 3rd most
frequent mutation. 542del7 mutation (exon 4) has not been previously described:
the consequence of this frameshift mutation is a premature stop codon resulting
in a non fonctional shortened protein product (class IB). It is a severe mutation
with pancreatic insufﬁciency. Except for FEV1 in 394delTT CF patients (p< 0.05),
the clinical phenotypes are not signiﬁcantly different with 394delTT and 542del7
mutations from all our group.
Conclusions: 1. We observe uncommon mutations in this particular population
suggesting a founder effect. 2. 542del7, a novel mutation, cause a classical CF
disease.
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Spectrum of CFTR mutations was investigated in CF-patients from Siberia re-
gion of Russia. The DNA samples of 151 unrelated patients affected by CF,
classical form, living in Siberia region of Russia (and referred to our Institute
in 2005–2010 years) had been analyzed. Patients had been tested for CFTR
mutations: F508del, I507del, 1677delTA, CFTRdele2,3 (del21kb), R334W, R347P,
G551D, R553X, G542X, 2143delT, 2184insA, 394delTT, 306delTAGA, 3821delT,
L138ins, N1303K, W1282X, 2176insC, 2183delAA, 2183AA→G. In group of
151 tested patients (302 alleles) 105 patients (69.5%) were either homozygous
of compound heterozygous, 44 patients (29.1%) carried only one detected mu-
tation. Allelic frequencies for tested mutations were: 60.60% (F508del), 7.95%
(CFTRdele2,3 (del21kb)), 4.64% (2184insA), 2.32% (R334W), 1.32% (N1303K),
1.32% (2143delT) and 0.99% (394delTT), 0.99% (G542X), 0.99% (W1282X) and
0.66% (R347P), 0.66% (3821delT), 0.33% (R553X). We found one novel for
Siberia region mutation − 2-bp deletion in exon 20 (CFTR gene) − 3944delGT. Its
presence was supposed due to unusual electrophoresis proﬁle of DNA-fragments
(exon 20) and subsequently mutation 3944delGT was determined by sequence
analysis in DNA of two CF-patients from different regions of Siberia; and since
we had included testing of 3944delGT mutation in our CFTR-mutation panel for
screening DNA from patient affected by CF and for prenatal diagnosis in CF-risk
families in Siberia region of Russia. We observed also one large CFTR duplication
(intron 6 − exon 10). One sequence alteration near exon-intron boundary of exon 20
we study now. As a result: characterization of mutations on 254/302 (84.1%) CF-
chromosomes.
